Obermatt
See Similar Stocks →

Cognition Therapeutics

NAQ:CGTX · US19243B1026
PharmaceuticalsX-Small

360° View

no current rank
Price/Sales—
Price/Earnings43
Price/Book5
Dividend Yield—
Revenue Growth—
Profit Growth78
Capital Growth61
TSR 52w92
Leverage55
Liquidity8
Refinancing37
Combined—
Analyst Opinions100
Pro Holdings15
Opinion Changes50
Market Pulse41

Profile

CountryUSA
IndustryPharmaceuticals
SizeX-Small
TypePublic Company
ExchangeNASDAQCM
Founded2007
Employees25
Websitecogrx.com
ISINUS19243B1026
Last UpdateApr 2, 2026
Index & Theme
OphthalmologyNeurologyChronic DiseasesNeuroscienceCentral Nervous SystemBiotechnologyLife ScienceTherapeutics

Description

Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system, or…

Similar Stocks

The companies this stock is ranked against.

Compare Cognition Therapeutics with its peers
Enliven Therapeutics
NSQ:ELVN
62
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Fulcrum Therapeutics
NMQ:FULC
24
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Foghorn Therapeutics
NMQ:FHTX
49
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Aardvark Therapeutics
NSQ:AARD
29
CountryUSA
IndustryPharmaceuticals
SizeX-Small
Full Stock Analysis →
MBX Biosciences
NSQ:MBX
30
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Climb Bio
NMQ:CLYM
—
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →